chrisvoncsefalvay/vaers-outcomes huggingface dataset:
SHingles on back and torso; temperature of 101 degrees; Loss of appetite; This spontaneous case was reported by a consumer and describes the occurrence of HERPES ZOSTER (Shingles on back and torso), PYREXIA (temperature of 101 degrees) and DECREASED APPETITE (Loss of appetite) in a 55-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 026A21A) for COVID-19 vaccination.     No Medical History information was reported.    On 02-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 05-Apr-2021, the patient experienced HERPES ZOSTER (SHingles on back and torso), PYREXIA (temperature of 101 degrees) and DECREASED APPETITE (Loss of appetite). The patient was treated with DIPHENHYDRAMINE HYDROCHLORIDE (BENADRYL [DIPHENHYDRAMINE HYDROCHLORIDE]) at an unspecified dose and frequency. At the time of the report, HERPES ZOSTER (SHingles on back and torso), PYREXIA (temperature of 101 degrees) and DECREASED APPETITE (Loss of appetite) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Treatment medication include calamine lotion. No concomitant medication details was reported.
nausea; Dry heaves; really bad headache, Headache/pain felt like worst migraine; variable muscle pains; chills; increased heart rate; no appetite.; Head felt hot; This is a spontaneous report from a contactable nurse. This 75 year reported female nurse (patient) reported.  A 75-year-old female patient received a dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, Formulation: Solution for injection, Lot Number: EN6201, Expiration date: unknown), via unspecified route, administered in left arm on 17Feb2021 (at the age of 75-year-old) as dose 2, single for COVID-19 immunization. Patient received a dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, Formulation: Solution for injection, Lot Number: unknown, Expiration date: unknown), via unspecified route, administered on 27Jan2021 (at the age of 75-year-old) as dose 1, single for COVID-19 immunization. The patient medical history includes Hypertension, Hyperparathyroidism, Drug hypersensitivity, Past drug event includes Candesartan induced unspecified reaction and metoprolol induced unspecified reaction. concomitant medications include Paracetamol (TYLENOL) from an unspecified date to unknown ongoing. On 18Feb2021 05:00 AM, after the vaccination, the patient experienced nausea, dry heaves, bad headache, variable muscle pains, chills, head felt hot, increased heart rate from usual 64 to 80 per minute, no appetite. Headache/pain felt like worst migraine ever - couldn't stop groaning. Ice packs on head all day. Woke midnight and headache gone but felt like migraine postdrome next day but by noon was free of all symptoms. The outcome of the events was recovered.  No follow-up attempts possible. No further information expected.  Follow-up (PRD/SRD (03Apr2021): This follow-up is being submitted to notify that the lot/batch number is not available despite the follow-up attempts made. Follow-up attempts have been completed and no further information is expected
Information has been received from an RN concerning a 31 year old female who on 4/14/01 was vaccinated with the 2nd dose of varicella virus vaccine live. Her 1st vaccination was in 10/00. Subsequently, the pt reported that she had become pregnant shortly following the 2nd dose of varicella virus vaccine live. Follow-up information was received from an RN who reported that the pt has been lost to follow-up but that shortly after she received the vaccine she indicated that she was pregnant but never returned a positive pregnancy test. Subsequently, the pt indicated that she "lost the baby" and that she did not feel it was from the vaccine. Follow-up information was received from an RN who reported that she has doubts about the validity of the report of pregnancy from this pt/employee. She stated that the employee had "issues", that despite repeated requests, the employee would not bring in proof of a positive pregnancy test or a doctor's examination. The pt is no longer employed at the facility. Due to the uncertainty of the report, the pt will be dis-enrolled from the pregnancy registry and the pregnancy will be considered unconfirmed. No further information is available.
I have an underlying condition called PMH. My hemoglobin went down after the first dose of the vaccine, but I was given Prednisone. After the second dose I had a fever of 101 the day after the vaccine and 103 on the second day. I was very tired for the next few days and I had trouble getting out of my chair. My hemoglobin was very low again and I was given a blood transfusion six days after the second dose of the vaccine. I had been taking Prednisone 15mg/daily since having the first dose so that protected me a little. I have not had any more problems since that time.
Myalgia, Fever, chills Narrative: Per nursing report: "took first Moderna vaccine yesterday [4/14]. C/o sore body all over, chills and states feels like she had a temp."
Patient was administered expired vaccine; This spontaneous case was reported by a nurse and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (Patient was administered expired vaccine) in a 39-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 025J20-2A) for COVID-19 vaccination.     No Medical History information was reported.    On 16-Mar-2021 at 11:50 AM, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 16-Mar-2021 at 11:50 AM, the patient experienced EXPIRED PRODUCT ADMINISTERED (Patient was administered expired vaccine). On 16-Mar-2021 at 11:50 AM, EXPIRED PRODUCT ADMINISTERED (Patient was administered expired vaccine) had resolved. Not Provided      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter considered EXPIRED PRODUCT ADMINISTERED (Patient was administered expired vaccine) to be not related.    No concomitant medication information was provided. It was reported that patient has no known allergies. It was reported that patient was contacted to received a second full dose as soon as possible.
This case was reported by a other health professional via call center representative and described the occurrence of injection site erythema in a 54-year-old female patient who received SHINGRIX for prophylaxis. On 3rd November 2018, the patient received the 1st dose of SHINGRIX. On 3rd November 2018, 3 hrs after receiving SHINGRIX, the patient experienced injection site erythema, injection site swelling, injection site warmth and injection site tenderness. On an unknown date, the outcome of the injection site erythema, injection site swelling and injection site tenderness were not recovered/not resolved and the outcome of the injection site warmth was recovering/resolving. It was unknown if the reporter considered the injection site erythema, injection site swelling, injection site warmth and injection site tenderness to be related to SHINGRIX. Additional details were provided as follows: Around 5 pm, the patient received SHINGRIX. By 8 pm, the patient had redness, swelling, heat and tenderness at the injection site. At the time of reporting, the patient still had the symptoms, though the heat had improved. The reporter consented to follow up.
Pt recvd HIB vax on 04MAR91; Next morning pt devel t102.4 & diarrhea; Pt reevaluated & found to have lost 8 oz in last 24 hrs;
17 year old patient administered a flublok, that is recommeneded for patients 18 years or more.
Pt reports left shoulder pain and swelling after 3rd Rabies vaccine injection. Did experience mild reaction to 1st and 2nd doses, temp of 97.4- pt denies breathing or swallowing difficulties. Localized reaction.
Erythema facial (erythema) Nasal congestion MEDI-0003701 is non serious spontaneous case from a physician in the USA involving Redness around the nose: (unlabelled, USA). The reporter causality is not provided to FluMist. This case is submitted according to the VAERS Safety Surveillance accelerated reporting agreement for FluMist. A physician from a pediatric clinic reported that a child received FluMist in 2004 and later in the day experienced nasal congestion and redness around the nose. The patient completely recovered. No other information is available. The reporter causality is not provided. Information received 6-23-2006 states Vaccine was administered at facility; patient was only seen once.
THE PATIENT DEVELOPED DIFFUSE ERYTHEMA OVER LEFT DELTOID AREA (VACCINATION SITE) AND SCATTERED PUSTULES on neck, torso, arms. Afebrile. No peripheral lymphadenopathy. Otherwise no generalized symptoms.
Develop diarrhea, headache, fever, abdominal cramping. Lasted two days. Unable to do anything for 2 days. Resolved with no medical intervention. Patient pushed fluids.
Vaccine was taken on May 14, 2019. Severe rash (hives) all over the body with severe itching, severe stomach bloating with diarrhea, lower lip swelling after 30 hours (on May 15, 2019) after the vaccine was taken .  This is the 2nd dose taken.  (The first dose was taken in May 2018 with minor feverish feeling and body pains).   The second dose only caused severe reaction.  Had to take Prednisone -6 day course  starting on May 17, 2019 (4th day after the second dose of the vaccine).  Then the reactions gradually diminished.
This initial non-serious spontaneous case, was received on 26-Sep-2017, from pharmacist and concerning a patient of an unspecified gender and age (reported as below 65 years). The patient's medical history and concomitant medications were not reported. On 06-Sep-2017, the patient was administered with FLUAD (dose: 0.5 ml, route of administration: intramuscular, batch number (reported as 178502), expiry date, anatomical location not reported) which was characterized as inappropriate age at vaccination. As FLUAD was indicated in individuals 5 years of age and older. It was reported that the patient had no issues after vaccination. The outcome of the events was not reported. The reporter considered this case as non-serious.
Received call from child health clerical dept. States client was fainting in and out. Pt states she felt funny. VS 109/75 P-58 at 11:25 a and again at 11:30 AM 106/75 P-61. Cool cloth applied for 10-15 min. Client able to walk out with no difficulty.
Information has been received from a physician concerning an 8-year-old white female who on 09-JUL-1999 at 11:40AM was vaccinated in the left arm with a first dose of Varivax (Lot # 628697/1838H). On 28-JUL-2006 the patient broke out with chickenpox. Subsequently, the patient recovered. No additional information is expected.
Headache, Fever, Reports chills, left arm swelling,fever 102. 7, and headache. Sick call today 1/20/2021. Narrative:
Developed pain, swelling redness and limited mobility of (L) arm 4 hours after vaccination. 24 hours after vaccination chills, disorientation/continued pain in (L) arm with weakness of (L) arm.
Mother stated 5 hours after vaccines were given pt was fussy along with swelling and redness (L) thigh where injection was given. Mother used cool compresses & Tylenol with symptoms resolving
Dizziness, Diarrhea, NauseaVomition, JITTERY, SWEATY Narrative:
arm hurts a little bit more than usual; pain at the injection site; pain in shoulder; This spontaneous case was reported by a consumer and describes the occurrence of PAIN (arm hurts a little bit more than usual), VACCINATION SITE PAIN (pain at the injection site) and ARTHRALGIA (pain in shoulder) in a 67-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 012L20A) for COVID-19 vaccination.     Concurrent medical conditions included Pain (She has always had refractory pain on her left arm and shoulder. On the day of the vaccination the pain happened at the injection site.). Concomitant products included METFORMIN and LEVOTHYROXINE for an unknown indication.    On 07-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 07-Jan-2021, the patient experienced VACCINATION SITE PAIN (pain at the injection site) and ARTHRALGIA (pain in shoulder). On 09-Jan-2021, the patient experienced PAIN (arm hurts a little bit more than usual). On 09-Jan-2021, VACCINATION SITE PAIN (pain at the injection site) and ARTHRALGIA (pain in shoulder) had resolved. At the time of the report, PAIN (arm hurts a little bit more than usual) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Patient also reported using Natural hormones concomitantly. No treatment medications were reported.
pt had myoclonic events @ time of sleep assoc temp w/DTP; neuro did not think it was a sx; mom prefers no further pertussis vax;
Headache, muscle aches first 3 days after the shot  8 days after shot my arm started hurting really bad it was swollen, day 9 woke up with a round  red circle at injection site and it was very stiff and itchy
After receiving first COVID vaccine, patient walked out of the immunization room and up towards the photo department where she reported tunnel vision then fainted into her mother's arms. Patient instantaneously recovered and sat on the floor. Technician was told about the incident where she gave her a bottle of water and a granola bar. Patient reported not having anything to eat or drink prior to the vaccine. Pharmacy manager called 911 for EMS to tend to patient. Patient did not go with ambulance.
COVID 19 Treatment; COVID 19 Treatment; Dose #1: Pfizer/ Dose#2: Pfizer/ Dose #3: Pfizer/ Dose #4: Moderna; This is a spontaneous report received from a non-contactable reporter(s) (Consumer or other non HCP) from product quality group. The reporter is the patient.  A 66-year-old male patient received bnt162b2 (BNT162B2), on 26Mar2021 as dose 1, single (Lot number: ER8727), on 18Apr2021 as dose 2, single (Lot number: EW0161) and on 09Nov2021 as dose 3 (booster), single (Lot number: 320308D) at the age of 64 years for covid-19 immunisation; elasomeran (MODERNA COVID-19 VACCINE), on 13Jun2022 as dose 4 (booster), single (Lot number: 014B22A) for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. No known allergies. The following information was reported: INTERCHANGE OF VACCINE PRODUCTS (medically significant) with onset 13Jun2022, outcome "recovered", described as "Dose #1: Pfizer/ Dose#2: Pfizer/ Dose #3: Pfizer/ Dose #4: Moderna"; DRUG INEFFECTIVE (medically significant), COVID-19 (medically significant), outcome "recovered" and all described as "COVID 19 Treatment". Therapeutic measures were taken as a result of drug ineffective, covid-19 included Paxlovid from 26Oct2023 to 31Oct2023.  No follow-up attempts are possible. No further information is expected.
1st dose: pre-covid, 2nd dose: 18-APR-2023; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of drug dose administration interval too long in a 69-year-old male patient who received Herpes zoster (Shingrix) (batch number 9372K, expiry date 05-AUG-2024) for prophylaxis.   Previously administered products included Shingrix (1st dose received in pre covid  (february or march)).   On 18-APR-2023, the patient received the 2nd dose of Shingrix. On 18-APR-2023, an unknown time after receiving Shingrix, the patient experienced drug dose administration interval too long (Verbatim: 1st dose: pre-covid, 2nd dose: 18-APR-2023). The outcome of the drug dose administration interval too long was unknown.   Additional Information: GSK receipt date: 18-APR-2023 Lot number and expiration was for the second shot of the vaccine series.  The reporter consented to follow up. The patient received 2nd dose of Shingrix, later than the recommended interval, which led to lengthening of vaccination schedule.
Patient presented to pharmacy on day 21 (6/22/21) post 1st dose so she can receive her 2nd dose. The date of her 1st dose was overlooked and she received her 2nd Moderna dose on day 21. Patient was contacted on 6/23/21 regarding the error - She reports no adverse effects other than a sore arm. Patient was educated that no additional doses are needed. She was instructed to contact the pharmacy and her PCP if she experiences any adverse effects related to the vaccine.
About 18 hours after arm swollen and hard and red and heat from arm area, aches, pain, nausea,  thirsty.   After 12 hours of really feeling like i was hit by a car.....all of the sudden like magic all was gone except my arm is still oval 8 ? red spot and hard still
Patient is a 40 y.o. female patient of MD was in hospital with COVID-19 related respiratory symptoms with hypoxia.  She has been vaccinated.  Rule out COVID due to lack of the booster and she has, shortness of breath and had hypoxia with pulse ox documented to be 83% in the emergency room.  She was diagnosed to have COVID-related respiratory illness and due to hypoxia was found to be candidate for remdesivir which was given to her in the ER and continued.  She was given steroid pulse oximetry her nose swab was positive for MRSA she needing Bactroban and getting escalation due to COVID.  She has unremarkable other labs and although her cholesterol was high she is being treated for the same she has been pleasant awake oriented for diagnosis and she is being discharged home with a prescription of prednisone and Lipitor and no need for antibiotics we will continue Bactroban on discharge she will benefit from COVID booster vaccine and advised to control metabolic syndrome.  She does not smoke although her fiancé does.  She is being discharged and will follow up in clinic in 7 days that she was given instructions about COVID and his contagiousness and possibility of other family members having similar illness.    Pneumonia due to COVID-19 virus She has lower respiratory tract symptoms with hypoxia with COVID-related infection she will be treated with the help of IV remdesivir steroids oxygen breathing treatments as well as remdesivir.  She will be treated with fluids fluids monitor the labs.    91223: She is doing better Continue oral steroids on discharge   Hyperlipidemia She has hyperlipidemia history check a lipid panel and treat accordingly  91223: Her lipid panel is abnormal start Lipitor on discharge   Hypertension She has hypertension blood pressure has been normal    Depression She has depression currently on medicine for the same she will be treated with the help of antidepressant  She has been on Seroquel she is doing well currently on medications for the same
2 DAYS AFTER VACCINE RED BUMPS AND BOILS/PUSTULES DEVELOPE AT AND AROUND VACCINATION SITE
Patient received a dose of Bivalent vaccine but then noted her received the bivalent dose on 102/17/2022 so this ended up being a duplicative dose.
fatigue, patient stated that he had numbness in mouth, and he's noticed that he was developing red hives all over his body, patient stated that hives will go away then come back in a different location.
Ache in arm at injection site as well as the shoulder area. It's 3 1/2 weeks later and the shoulder pain is deep and severe. Arm movement is compromised.
This spontaneous report was received from a nurse and refers to an unknown number of patients of unknown age and gender. No information regarding the patients' pertinent medical history, drug reactions or allergies and concomitant therapies was provided. Since an unknown date in January 2017, the patients were administered improperly stored doses of LIQUID PEDVAXHIB (doses, anatomical location, route of administration, lot # and expiration date were not reported). The administered doses of vaccine underwent a temperature excursion between 32 degrees Fahrenheit (F) to 35 degrees F, and between 47 degrees F to 77 degrees F, a time frame was not yet determined. There was no previous temperature excursion reported and a digital data logger was not involved. No adverse effect was reported. No product quality complaint (PQC) was involved. This one of two reports received from the same reporter. Additional information has been requested.; Sender's Comments:  US-009507513-1704USA014024:
Patient had no adverse event or outcome. After administration, was discovered that vaccine refrigerator was out of temperature range. Patient is notified and offered re-vaccination.  Patient also got Influenza vaccine on  9/28/2021 that was later discovered to be in the same refrigerator. Also no adverse effects, also notified and offered re-vaccination.
The shot was given on Thursday. Flulike symptoms (chills, body aches, nausea, fatigue, headache) and left arm soreness continued through Friday and Saturday. Sunday I was feeling fatigued, but otherwise back to normal. I awoke Monday morning with severe  abdominal pain, shortness of breath, back /chest pain, fever, body aches, vomiting. I went to the Hospital Emergency Department and was subsequently diagnosed and treated for acute pancreatitis (and diverticulitis).
Diagnosed with ITP following MMR vaccine.  Received vaccine 3/8/22, symptoms onset 4/9/22.
Received Tdap, MENACTRA, HPV on 4-30-14 (Wed). Thurs (L) arm swollen, red, tender; seen in ER; told by ER Dr. should not have received MENACTRA - too young. Follow up in HC - encouraged to take Ibuprofen, ice and BENADRYL for comfort. Education provided around Tdap and MENACTRA.
arm is sore; This is a spontaneous report from a non-contactable consumer. A female patient of an unspecified age received BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE), via an unspecified route of administration on an unspecified date at a single dose for COVID-19 immunisation. The patient's medical history and concomitant medications were not reported. The reporter is a Pfizer employee and her daughter's physical therapist mentioned to her that she got the Pfizer vaccine and her arm was sore. The outcome of the event was unknown.  No follow-up attempts are possible; information about lot/batch number cannot be obtained.
Morning after injection arm was stiff, sore and weak. Pain increased with each couple of days around rotator cuff. Range of motion was greatly diminished. Trying to do daily activities aggravates shoulder joint w/ intense pain and clicking.
Nursing home pt developed an Influenza A Virus infection /p receiving Influenza Virus Vaccine
was given expired dose of Menactra on 22APR2022, with no reported adverse event; Initial information received on 25-Apr-2022 regarding an unsolicited valid non-serious case received via pharmacist.  This case involves an unknown age and unknown gender patient who experienced was given expired dose of menactra on 22apr2022, with no reported adverse event while receiving vaccine meningococcal a-c-y-w135 (d conj) vaccine (Menactra).  The patient's past medical history, medical treatment(s), vaccination(s) and family history were not provided.  On an unknown date, the patient received a dose of suspect meningococcal a-c-y-w135 (d conj) vaccine (dose, route, lot number and administration site: unknown) for prophylactic vaccination.  Reportedly patient was given expired dose of menactra on 22-Apr-2022, with no reported adverse event (expired product administered) (unknown latency) following the administration of meningococcal a-c-y-w135 (d conj) vaccine and asks should it be repeated?  Action taken: not applicable.  It was not reported if the patient received a corrective treatment for the event (was given expired dose of Menactra on 22APR2022, with no reported adverse event).  At time of reporting, the outcome was Unknown for the event was given expired dose of menactra on 22apr2022, with no reported adverse event.  This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holder's compliance with the requirements set out in the guidelines. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error.